Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$34.72K$34.72K−50.2% vs Q1 2020 Net Income-$2.68M-$2.68MN/M vs Q1 2020 EPS Diluted-$0.06-$0.06N/M vs Q1 2020 Gross Profit$32,194−49.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$289,948N/M Margins · derivedGross margin92.7%+1.7 pt vs Q1 2020
Operating margin-1700.8%−725.6 pt vs Q1 2020
Net margin-7722.5%
ended Mar 31, 2021 · filed May 24, 2021 · 54 d after period end